{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"}],"units":"Participants"}],"description":"The primary outcome is the percentage of patients achieving at least a major response rate at 24 weeks post commencing treatment. A major response rate is defined as a greater than 50% reduction in paraprotein measurement - this is in line with international recognised response criteria for the disease under investigation. In this single arm study all patients receiving treatment were considered applicable for endpoint analysis. There is no comparison as there is only one arm.","groups":[{"description":"Pembrolizumab: 200 mg IV dose given on day 1 of a three week cycle\n\nRituximab: 375 mg/m2 IV dose given up to 8 times in the trial","id":"OG000","title":"Pembrolizumab and Rituximab"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"24 weeks","title":"Percentage of Patients Achieving at Least a Major Response Rate at 24 Weeks Post Commencing Treatment","type":"PRIMARY","unitOfMeasure":"Participants"}